Hannah Sachs-Wetstone

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email.Last week, Pfizer announced promising results from their late-stage clinical trial for an experimental vaccine candidate for respiratory syncytial virus (RSV), which has been causing serious concern in recent weeks. The vaccine was administered to pregnant individuals with the goal of protecting infants upon their birth. The trial found that the vaccine candidate was 82 percent effective against severe illness for infants in their first 90 days and 69 percent effective through their first six months. The Pfizer vaccine is one of several candidates that are expected to undergo review from the US Food and Drug Administration later this year.As the Ebola outbreak in Uganda continues, three experimental vaccine candidates aimed at protecting against the Sudan strain of the virus (for which there are no approved vaccines) have been sent to Uganda to be administered to people and to help generate more data for clinical trials. The candidates include one vaccine developed by Oxford University and manufactured by the Serum Institute, one developed by the National Institute of Allergy and Infectious Diseases and licensed to the Sabin Vaccine Institute, and one candidate from Merck. Doses of all three vaccines will be deployed to Uganda through a joint effort with the World Health Organization and the United States Centers for Disease Control and Prevention in the coming weeks and months.A new study conducted in Mali showed that a single dose of monoclonal antibodies provided protection from malaria infection for up to six months. While monoclonal antibodies are notoriously expensive to produce and complex to administrate, the lab-made antibodies employed in the study could prove to be a key tool to protect children and pregnant individuals in the fight against malaria, at least in the short-to-medium term. This study follows another last year, which showed that intravenous administration of the antibody prevented infection in all nine participants.

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email.While the COVID-19 pandemic has led to serious setbacks in progress against tuberculosis (TB) with mortality now rising again after a slow but steady decline before the pandemic, COVID-19 has also demonstrated the feasibility of large-scale investment into the rapid development of urgently needed technologies when political will and a sense of urgency exists. Researchers were working on developing new tests, drugs, and vaccines for TB before the pandemic, including one vaccine candidate currently in advanced clinical trials that was developed by GSK and the Bill & Melinda Gates Foundation. Now, powerful technologies that were employed in the development of vaccines for COVID-19, like messenger ribonucleic acid (mRNA), are starting to be employed against TB, with BioNTech and Pfizer planning trials of an mRNA TB vaccine in the next few months.The World Health Organization (WHO) has published its first-ever list of fungal priority pathogens in response to the expanding geographic range of dangerous fungi due to climate change, the rise in cases of fungal disease during the COVID-19 pandemic, and the growth in resistance of fungal diseases to treatments. The list includes 19 pathogens that have been identified as posing the greatest threat to human health. The goal of publishing the list is to catalyze funding for research into fungal infections, which receives less than 1.5 percent of all funding for infectious diseases, as well as to encourage improvements to the treatment guidelines for these infections.The University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP) recently published a draft of a Coronavirus Vaccines Research and Development Roadmap, a project supported by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, for public review and comment. The roadmap, which builds on lessons learned from the development of successful COVID-19 vaccines, identifies strategies to develop effective vaccines for new COVID-19 variants as well as coronaviruses that have yet to emerge. In particular, the roadmap emphasizes the need for durable, broadly protective vaccines that are simple to deliver and that protect against multiple coronaviruses.

At GHTC, we get to read stories every day about incredible innovations in global health. Most of the technologies we see are inventive, some are revolutionary, and a few are so unusual, one might think they were ripped from the pages of a science fiction novel. Now, we’re testing how well you know these global health technologies with our annual Halloween game: the TRICK or TREATment quiz.For each question, we will present a description of a global health technology. Choose TREATment if you believe this innovation exists. Choose TRICK if you think we are trying to pull one over on you and, instead, the product is still in development or is just a figment of our imagination. 

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email.Regulators in Zimbabwe have approved long-acting injectable cabotegravir, (CAB-LA), making the country the first in Africa and the third in the world (after Australia and the United States) to approve the drug. The World Health Organization (WHO) called the approval a “crucial step” and noted that it would support the implementation and distribution of the prevention method in the country to maximize impact. WHO previously issued a recommendation for CAB-LA in July that cited its high efficacy in reducing HIV transmission among high-risk individuals.A research team from the University of Cape Town published new findings showing evidence that a cancer drug currently in clinical trials has shown potential in protecting from, curing, and preventing malaria transmission. The investigational drug, sapanisertib, acts by killing the human malaria parasite in the liver, the human host red blood cell, and when it divides sexually within the host red blood cells. This is an incredibly significant finding as the drug exhibits a novel mechanism of action as well as activity against multiple stages of the parasite life cycle. Further research could lead to the development of a critically needed novel malaria drug that contributes to malaria control and elimination efforts as well as addresses drug resistance.The United States provided Gilead Sciences’ antiviral, remdesivir, and Mapp Biopharmaceutical Inc’s experimental antibody drug, MBP134, to Uganda in an effort to help prevent further cases and deaths in the outbreak, which is now the largest outbreak of the Sudan strain of Ebola in over 20 years. Both Ugandan and US government officials noted the need for treatment to protect the lives of health care workers, which is a key step in containment.  

2021 was a year of significant progress in the global effort to eradicate polio, despite challenges due to the COVID-19 pandemic. Unfortunately, as we sit toward the close of 2022, the outlook is less optimistic. Recently, polio has been popping up in the news with increasing frequency as outbreaks have occurred around the world. In observance of World Polio Day on October 24, GHTC is reflecting on the biggest news about this year’s polio outbreaks and on the connection between this year’s outbreaks and polio vaccines, as well as the potential of new vaccines to contribute to eradication. The development of a vaccine against polio was one of the most important and impactful medical technological breakthroughs of the last century and since then, more than 2.5 billion children have been vaccinated through the Global Polio Eradication Initiative, a public-private partnership led by national governments, the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention, UNICEF, the Bill & Melinda Gates Foundation, and Gavi, the vaccine alliance. Two types of vaccines are used for polio. The oral polio vaccine (OPV) is used in mass vaccination campaigns in low- and middle-income countries, while the inactivated polio vaccine, which is more expensive and complex to administer, is used in most high-income countries. One of the largest remaining challenges in global polio eradication efforts is that in rare cases, the use of OPV in areas of low vaccine coverage can lead to vaccine-derived polio, which partly accounts for the recent rise in cases. For a short time after OPV immunization, children have the weakened vaccine-virus in their bodies and excrete it. In areas of low immunization, if the excreted vaccine-virus circulates for an extended period of at least a year, it could change genetically to the circulating vaccine-derived poliovirus.Vaccine-derived polio has emerged due to outbreaks of the type 2 virus, which was removed from the oral vaccine by WHO in 2016 after it was declared to be eradicated. In 2020, in response to vaccine-derived outbreaks, WHO granted an emergency use authorization for a novel oral vaccine that is aimed at type 2 poliovirus (nOPV2) and is less likely to lead to vaccine-derived cases. The first-ever vaccine authorized under WHO’s Emergency Use Listing process, nOPV2 was rolled out in March 2021 and doses of the vaccine have already been delivered in over 20 countries. However, supply constraints and challenges in vaccine uptake need to be addressed for nOPV2 to be rolled out more widely. Full immunization throughout populations would prevent the spread of vaccine-derived polio, highlighting the importance of employing polio vaccines in order to prevent the outbreaks we have seen this year.Read more about this year’s spate of outbreaks:"In new setback for eradication campaign, poliovirus from Pakistan shows up in Africa" (Science, 2/17/2022)"Polio is found in the U.K. for the first time in nearly 40 years. Here's what it means" (NPR, 6/22/2022)"Wastewater monitoring identifies polioviruses in New York City" (STAT, 8/12/2022)"The Guardian view on polio: we have the tools to tackle this old enemy" (The Guardian, 8/16/2022)Read more coverage about vaccine-derived polio:"What to know about polio, a disease once again vying for attention" (STAT, 7/26/2022)“New polio cases highlight the urgency of eradication” (Think Global Health, 8/16/2022)"Polio was almost eradicated. This year it staged a comeback." (The New York Times, 8/18/2022)"Polio spread in Israel, US, UK highlights extremely rare risk of oral vaccine" (The Times of Israel, 8/21/2022)“Polio Is Exploiting a Very Human Weakness” (The Atlantic, 9/16/2022) Read more about nOPV2:"New polio vaccine against strain that threatens eradication is safe and generates immune response" (MedicalXpress, 12/10/2020)"WHO nod to first emergency use vaccine can tackle rising vaccine-derived poliovirus cases" (Down to Earth, 12/16/2020)“Independent experts advise move to next use phase for novel oral polio vaccine type 2” (GPEI press release, 10/10/2021)"The polio threat continues to grow—but a new vaccine could make a difference" (Time, 8/31/2022)“Supply issues a major challenge to polio vaccination programs” (MedPage Today, 10/4/2022)“Opinion: The US needs to prepare to introduce the novel oral polio vaccine” (The BMJ, 10/4/2022)Read more about polio funding:"Opinion: Polio eradication is in sight. Don’t stop funding it now" (STAT, 10/16/2022)“Gates Foundation pledges $1.2B to eradicate polio. Here’s why it’s been a struggle for decades” (Associated Press via PBS News Hour, 10/16/2022)“Bill & Melinda Gates Foundation pledge $1.2 billion to eradicate polio” (Reuters, 10/17/2022)“Global leaders commit $US2.6 billion at World Health Summit to end polio” (UNICEF press release, 10/18/2022)More information about World Polio Day can be found here. 

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. The National Institute of Allergy and Infectious Diseases and the Democratic Republic of the Congo’s National Institute for Biomedical Research are co-leading a clinical trial evaluating the safety and efficacy of the antiviral drug, tecovirimat (TPOXX), in mitigating symptoms and preventing serious outcomes in 450 adults (including pregnant individuals) and children with monkeypox. SIGA Technologies, Inc.’s TPOXX is approved for the treatment of smallpox in the United States. The drug impedes the spread of virus in the body by preventing virus particles from exiting human cells. Trial participants will be randomly assigned to receive the oral pill or placebos twice daily for two weeks. The World Health Organization (WHO) has announced that a clinical trial of vaccines aimed at preventing the rare Sudan strain of Ebola could start within weeks, pending regulatory approvals from the Ugandan government. There is no vaccine for the Sudan strain, which is behind the rapidly growing outbreak in Uganda. The trial will test two vaccines in development that have shown potential to treat this strain. Details about the specific vaccine candidates were not released. While the Sudan strain is less transmissible and has had a lower fatality rate in past outbreaks, compared to the Zaire strain, the Ugandan outbreak is incredibly concerning, and vaccines are urgently needed. By raising public awareness of emerging diseases and the need for laboratory capacity to address them, COVID-19 has inspired several Asian countries, including India, to invest in advanced biosafety laboratories. These labs are needed for working on dangerous pathogens and live viruses like SARS-CoV2. Some researchers have expressed concerns about the high cost of maintaining these facilities due to extensive safety measures including extra security, self-closing doors, and filtered air, among others. Concerns have also arisen about the potential risk of these labs handling extremely dangerous pathogens, however new labs could also improve overall safety practices that would reduce this risk. These new labs could play an important role in supporting more vaccine research, including for endemic infectious diseases in the region, as well as improving working conditions for researchers.